Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 20th January 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Injectable omeprazole ‘can be used within rules’, BHA confirms
"Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease" - Dr Mike Hewetson. 

Vets had been previously advised against using the drug owing to traces of testosterone

The British Horseracing Authority (BHA) has announced that injectable omeprazole, manufactured by Bova UK, can now be used in racehorses ‘within rules’.

Veterinary professionals had previously been advised against possessing, using or administering the drug in racehorses after small traces of testosterone were discovered in a batch of the product last year.


Although independent experts said there could be no adverse effects on equine health or equestrian sport, BOVA took immediate action to identify and eliminate the ingredient that contained the testosterone.


In September 2019, the product was declared free of testosterone and has since continued to be used in Australian racehorses after guidance from Racing NSW. Tests on multiple samples of injectable omeprazole ahead of sale have also since demonstrated the product to be free of testosterone. 


Dr Mike Hewetson from the Royal Veterinary College explained: “Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease, particularly those affected by glandular gastric disease.”

A recent blind clinical trial of Bova’s injectable omeprazole found that healing rates for both glandular and squamous gastric disease were four times higher with injectable omeprazole than with a registered oral product.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.